TY  - JOUR
AU  - Anwar, Hoda
AU  - Sachpekidis, Christos
AU  - Winkler, Julia
AU  - Kopp-Schneider, Annette
AU  - Haberkorn, Uwe
AU  - Hassel, Jessica C
AU  - Dimitrakopoulou-Strauss, Antonia
TI  - Absolute number of new lesions on18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab.
JO  - European journal of nuclear medicine and molecular imaging
VL  - 45
IS  - 3
SN  - 1619-7089
CY  - Heidelberg [u.a.]
PB  - Springer-Verl.
M1  - DKFZ-2018-00120
SP  - 376 - 383
PY  - 2018
AB  - Evaluation of response to immunotherapy is a matter of debate. The aim of the present study was to evaluate the response of metastatic melanoma to treatment with ipilimumab by means of18F-FDG PET/CT, using the patients' clinical response as reference.The final cohort included in the analyses consisted of 41 patients with metastatic melanoma who underwent18F-FDG PET/CT before and after administration of ipilimumab. After determination of the best clinical response, the PET/CT scans were reviewed and a separate independent analysis was performed, based on the number and functional size of newly emerged18F-FDG-avid lesions, as well as on the SUV changes after therapy.The median observation time of the patients after therapy was 21.4 months (range 6.3-41.9 months). Based on their clinical response, patients were dichotomized into those with clinical benefit (CB) and those without CB (No-CB). The CB group (31 patients) included those with stable disease, partial remission and complete remission, and the No-CB group (10 patients) included those with progressive disease. The application of a threshold of four newly emerged18F-FDG-avid lesions on the posttherapy PET/CT scan led to a sensitivity (correctly predicting CB) of 84
LB  - PUB:(DE-HGF)16
C6  - pmid:29124281
DO  - DOI:10.1007/s00259-017-3870-6
UR  - https://inrepo02.dkfz.de/record/132432
ER  -